Purdue University

Purdue e-Pubs
BIRS Africa Technical Reports

Biotechnology Innovation and Regulatory
Science Center Global Community

11-1-2021

Improving the Outcome of GMP Inspections by Improving
Proficiency of Inspectors through Consistent GMP Trainings
Solomon Shiihi
Purdue University, sshiihii@purdue.edu

U G. Okafor
Purdue University, uokafor@purdue.edu

Z Ekeocha
Purdue University, zekeocha@purdue.edu

S Byrn
Purdue University, sbyrn@purdue.edu

K Clase
Purdue University, kclase@purdue.edu

Follow this and additional works at: https://docs.lib.purdue.edu/birsafricatr

Recommended Citation
Shiihi, Solomon; Okafor, U G.; Ekeocha, Z; Byrn, S; and Clase, K, "Improving the Outcome of GMP
Inspections by Improving Proficiency of Inspectors through Consistent GMP Trainings" (2021). BIRS
Africa Technical Reports. Paper 6.
http://dx.doi.org/10.5703/1288284317433

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries.
Please contact epubs@purdue.edu for additional information.

1

Improving the Outcome of GMP Inspections by Improving Proficiency of Inspectors
through Consistent GMP Trainings
S.U. Shiihi 1, U.G. Okafor 2 Z. Ekeocha 3, S. Byrn 4, K. Clase 5

ABSTRACT
Approximately 90% of the pharmaceutical inspectors in a pharmacy practice regulatory agency in West Africa
have not updated their training on Good Manufacturing Practice (GMP) inspection in at least eight years. However,
in the last two years the inspectors relied on learning-on-the job skills. During this time, the agency introduced
about 17% of its inspectors to hands-on GMP trainings. GMP is the part of quality assurance that ensures the
production or manufacture of medicinal products is consistent in order to control the quality standards appropriate
for their intended use as required by the specification of the product. Inspection reports on the Agency’s GMP
inspection format in-between 2013 to 2019 across the six geopolitical zones in the country were reviewed
retrospectively for gap analysis. Sampling was done in two phases. During the first phase sampling of reports was
done by random selection, using a stratified sampling method. In the second phase, inspectors from the Regulatory
Agency from different regions were contacted on phone to send in four reports each by email. For those that
forwarded four reports, two, were selected. However for those who forwarded one or two, all were considered.
Also, the Agency’s inspection format/checklist was compared with the World Health Organization (WHO) GMP
checklist and the GMP practice observed. The purpose of this study was to evaluate the reporting skills and the
ability of inspectors to interpret findings vis-à-vis their proficiency in inspection activities hence the efficiency of the
system. Secondly, the study seeks to establish shortfalls or adequacies of the Agency’s checklist with the aim of
reviewing and improving in-line with best global practices. It was observed that different inspectors have different
styles and methods of writing reports from the same check-list/inspection format, leading to non-conformances.
Interpretations of findings were found to be subjective. However, it was also observed that inspection reports from
the few inspectors with the hands-on training in the last two year were more coherent. This indicates that
pharmaceutical inspectors need to be trained regularly to increase their knowledge and skills in order to be kept
on the same pace. It was also observed that there is a slight deviation in placing sub indicators under the GMP
components in the Agency’s GMP inspection format, as compared to the WHO checklist.
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1. INTRODUCTION
There are a number of systems that heavily regulate
the pharmaceutical industry (Plumb, 2005). It is
required by the World Health Organization (WHO),
and the major markets, that products be
manufactured in-line with Good Manufacturing
Practice (GMP) for acceptability into both local and
international
market
place
(World
Health
Organization, 2007). GMP is defined as “a part of
quality assurance which ensures that products are
consistently produced and controlled to the quality
standards appropriate to their intended use and as
required by the marketing authorization and products
specifications” (Sarvari et al., 2020). The major role
of GMP is to prevent particulates and micro-organism
contamination of the product, especially from the
operatives of the plant in the manufacturing cubicle,
particulates from the equipment, chemicals leached
from the product contact parts and from other
products being manufactured (Plumb, 2005). GMP
also entails performing qualifications and validations,
availability of all the needed resources with clear
instructions and procedures written. In addition GMP
requires that all the personnel are trained to carry out
their functions correctly with proper records keeping
from the beginning of the manufacturing to the
distribution. Proper storage and recall systems and
feedback mechanisms must be put in place
(Chaudhari et al., 2014). GMP is a tool used to
prevent contamination and cross contamination of
products from other products produced within the
same pharmaceutical manufacturing facilities.
Because of this, extensive and regular cleaning is
required (Plumb, 2005).
Good Manufacturing Practice is a system put in place
to guarantee the safety of the end user of a product
(Hewitt et al., 2007). There are practices that require
conformity to the guidelines recommended by the
regulatory agencies. For these guidelines to be
implemented in manufacturing industries there must
be inspections and monitoring of such industries by
the regulatory bodies. There is, therefore, a need for
the regulators to be knowledgeable and competent in
order to effectively inspect and monitor industries for
the implementation of the GMP and/or enforcement of
its compliance. The World Health Organization
(WHO) developed a universally appropriate and
flexible competency frame work for inspectors, which
is to support and strengthen pharmaceutical
regulators. On this account, “competency” was

defined as the knowledge, skills, attitude and behavior
developed through education, training and experience
(World Health Organization, 2019b). Competence
here connotes independent gathering of information
through objective review, observation and open
communication that guides one to determine
acceptability of information by comparing with the
established criteria. As time went on, WHO, in their
guide on quality system requirement for GMP
proposed specified competency requirement of an
inspector as follows:
•
•

•

•

•
•

a GMP inspector should be able to perform his or
her duties with tact, integrity and character
be qualified academically and knowledgeable in a
pharmaceutically
related
discipline
like
scientific/technology.
have a requisite working knowledge and should
be conversant with the GMP guidelines of WHO
for pharmaceutical products.
should also be familiar with procedures of GMP
inspection of the relevant national regulatory
authority.
must have completed a relevant training course
on quality management system and auditing.
before conducting an inspection, the inspector
must have been appropriately trained on the
techniques and current procedures of GMP
inspection (World Health Organization, 2019a).

Due to the constant emerging trends in the
pharmaceutical manufacturing sector, untrained/nonregular trained regulators on GMP inspections may
not be up-to-date with such new trends therefore
lagging behind the regulated pharmaceutical
companies. Improper and/or inadequate regulation
leads to non-compliance to GMP and subsequent
availability of poor quality/counterfeit medicines.
Basic qualifications to be an Inspector
A GMP inspector is a member of personnel that is
trained in all areas relevant to quality assurance and
quality control (QA/QC) management, including
production procedures, distribution, inspection
methodology and drug control (Tomić et al., 2010). A
qualified inspector should be a pharmacist graduate,
chemist or scientist with practical manufacturing
experience
or
industrial
back
ground
in
pharmaceutical production and should be a team
player (HPRA, 2018)
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Role of the inspector
The primary responsibility of an inspector is to inspect
and present a detailed factual report on standards of
manufacturing and controls applied to specific
products. Inspection also applies to all the
manufacturing processes and the facility itself.
Inspection should not just be a compilation of an
inventory of faults, irregularities and discrepancies but
should also advice the pharmaceutical industry being
inspected in a manner, which in the opinion of the
inspector will serve the interest of the public(World
Health Organization, 2007). In summary:
•
•
•

GMP compliance guarantees safety of the end
user of a product (Hewitt et al., 2007).
GMP inspections promotes GMP compliance.
For effective GMP inspection, the inspector must
be knowledgeable and because GMP is evolving,
the GMP inspectors need regular GMP trainings
to enable them carry out effective inspections.

It is no longer news that about 70% to 90% of drug
needs in most countries in Sub-Saharan Africa are
imported (Conway et al., 2019). Yet, most African
leaders have policies on paper that are made to
encourage an increase in local production of
pharmaceuticals in their respective countries.
Whether these policies are genuine and meant for
implementation is another major concern.
The National Drug policy (NDP) for Nigeria
encourages increased local production of essential
drugs as its major goal amongst others
(www.wjrp.net). However, in reality, there seems to be
no concrete mechanism put in place to achieve this.
Inadequate power supply has been one of the main
challenges to manufacturers and is not being
addressed.
In the recent past the Pharmaceutical society of
Nigeria called on the Federal Government of Nigeria
to increase local production of essential drugs from
the present 45% to at least 75% by injecting funds into
the
Pharmaceutical
manufacturing
sector
(www.niropharm.org).
Furthermore, the World Health Assembly initiated
“Improving Access to medicines in developing
countries through technology transfer and local
production” (Anderson et al., 2012). Also, at the
International Conference on Primary Healthcare in
Alma-Ata in 1978, the availability of quality medicinal
products was identified as an important component
for healthcare delivery (Gouveia et al., 2015).
However, the success of local production hinges on
some vital factors like infrastructure and effective

regulation. The primary problem is the high taxation
on the Active Pharmaceutical Ingredients (APIs) and
other raw materials. Both APIs and drug products are
subject to high taxes and tariffs, causing increased
prices and decreased incentives to manufacture
drugs (Ubajaka et al., 2016).
Challenges
of
building
and
operating
manufacturing industries in the sub-Saharan
Africa
Both the private and public sectors have roles in
building and successfully running industries in any
country. To the private sector, the drive to do business
is the market feasibility, or the market demand. Unlike
the private sector, the public sector has enormous
responsibilities including but not limited to providing
infrastructures, provision of subsidies and reduction in
tax, issuing tenders as incentives to local producers,
creating and investing in talent and skill building
programs to create an enabling environment for
investors (Conway et al, 2019). In some countries in
Africa, donors have taken charge of the development
of pharmaceutical facilities by way of financing to
encourage local production of medicines in Africa. For
now it appears that local production is not yet efficient
in Africa. This may be due to issues like foreign
exchange insufficiency which will negatively impact
purchase of raw materials and cause high price of
finished product compared to importers such as China
(Vogel & Stephens, 1989). In addition, WHO
prequalification requires a quality standard and the
high operational cost to implement that standard
adversely affects local manufacturers (Anyakora et
al., 2017). Local manufacturers are especially
affected when tenders don’t come in the support to
incentive from donor agencies. However, there is
recent reason for optimism that the pharmaceutical
manufacturing situation is changing in Sub-Saharan
Africa. Out of Uganda, a country amongst the least
developed countries, a local Pharmaceutical
manufacturing company known as CIPLA Quality
Chemical ltd has achieved internationally recognize
standards of quality. Uganda was the first in SubSaharan Africa apart from South Africa, to gain WHO
prequalification (Anderson, 2010). Currently the
company produces for international agencies.
Effective regulation also plays a very important role in
the manufacture of quality and safe medicines. It can
only arise from sufficient knowledge of Good
Manufacturing Practice (GMP). Good Manufacturing
Practice is meeting quality standard by making sure
that products are consistently produced and
controlled to serve their appropriate intended use and
as required by marketing authorization, clinical trials
authorization and product specification (Gouveia et
al., 2015). The guiding principle of GMP is building
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quality into a product. It is not just assurance about
meeting specification but more importantly, it’s also
about the product being made by the same procedure
under the same condition every time (ChalonerLarsson et al., 1999). GMP comprised of the following
activities amongst others:
i.

There should be a clear definition of
procedures and processes with a systematic
review in place for risk management for the
purpose of consistently manufacturing
pharmaceutical products of the required
quality that comply with their specifications.
Also procedures and instructions must be
written in an unambiguous and clear
language (World Health Organization, 2007).

ii.

All aspects of manufacturing, including
facilities, should undergo qualification and/or
validation (World Health Organization, 2007).

iii.

All aspects of a quality manufacturing system
should be addressed including, appropriately
qualified and trained personnel, adequate
premises and space, suitable equipment and
services, appropriate materials, containers
and labels, approved procedures and
instructions, suitable storage and transport,
adequate personnel, laboratories and
equipment for in-process controls (World
Health Organization, 2007).

iv.

Personnel must be trained to ensure that
procedures are carried out correctly,
(Chaloner-Larsson et al., 1999).

Inspection and licensing
Pharmaceutical manufacturing facilities must be
inspected prior to licensure and certified as compliant
by regulatory authority prior to manufacturing
products for sale. Inspection and licensing are also a
fulcrum or basis on which the World Health
Organization operates in regards to certification
programmes on the quality of pharmaceutical
products to gain access into the international market.
Inspection is meant to assist and motivate a
manufacturer to correct deficiencies and comply with
GMP. The process of inspection of pharmaceutical
facilities is an activity that is meant to help the industry
comply with
guidelines that are recognized
internationally for GMP (Garg et al., 2013). GMP
inspections can have enormous consequences on a
company’s viability and may result in stiff regulatory
actions. Regulatory actions like product recalls can
result in negative corporate image and loss of sales

by halting a manufacturing line or placing an entire
facility on “hold” for gross violations (Woodcock,
2012). GMP inspections are also
tools for
assessment of manufacturers of pharmaceuticals by
regulatory agencies(Vaishnavi et al., 2011). There are
different types of audits and inspections (routine or
formal, concise or abbreviated, follow-up, special
inspections
and
quality
system
reviews
(www.slideshare.net; Garg et al., 2013) and varying
roles of individuals within regulatory agencies and the
pharmaceutical industry. The approaches to
inspections can be centered on the process, the
product, the system or all of these(Kate, 2002).
The inspection report writing follows the inspection
activity. A well written inspection report must be
effective in order to observe deficiencies (Dosland.,
2015). An inspection report should describe the facts,
the observation and the action needed to correct the
observations. The reporter should be objective
(www.who.int).
Creating knowledgeable and skilled regulators that
will translate to good inspection practices including
report writing. Developing regulators with good
inspection activities requires consistent training in the
GMP aspect of inspection. Training enables
inspectors to learn the GMP concepts and regulations
that apply to what they do. For the US Food and Drug
Administration (FDA),European Medicines Agency
(EMA), and Health Canada there are periodic
(annual) “refreshers” of GMP requirements that are
relevant to what the personnel do (Vesper.,et al
2018). Generally, the benefits of trainings cannot be
over- emphasized. They also save costs in the sense
that trained personnel will be more efficient for
effective regulation which will lead to availability of
safe, efficacious and quality medicine to the public.
This explains why some organizations organize
extensive and vigorous trainings for their staff
immediately after employment. A study to evaluate
the effectiveness of GMP training in enhancing
awareness and building capability of employees was
carried out in Malaysia. The study showed that the
employees after exposure to different areas of GMP
training namely personnel practice, premises and
equipment, documentation, production and product
quality control, improved their knowledge base about
GMP. Thus the report emphasized that training is
critical in improving the employee’s knowledge about
GMP in order to help improve the quality of product
manufactured (Singh et al., 2018). There is therefore
an absolute need for extensive and appropriate GMP
training for inspectors in developing countries(Garg et
al., 2013). An effective training programme is critical
as demonstrated by CIPLA chemical quality ltd, a
successful pharmaceutical manufacturing company in
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East Africa. CIPLA, Uganda, exposes their new
employees to a six month, vigorous training with a
series of written tests to assess the understanding of
the new employees into their prospective schedules
of duty. Those who do not perform well after six
months are given an extension of three months and
then dropped if considered incompetent after the
training for the additional period. However, at this
time, full salaries are not paid. The company is doing
well and the training forms part of their success story,
as indicated by the outcome of the several inspections
it has had. The company has been inspected several
times by WHO and have retained their WHO
prequalification.
Background information about the research
problem
Regulators are an essential part of the health
workforce and effective regulatory systems are an
essential component of health care systems,
contributing to better public health outcomes (World
Health Organization, 2010). It has been observed that
some of the regulated industries are ahead of the
regulators. It is also observed that about 90% of the
pharmaceutical inspectors of a Pharmacy Practice
Regulatory Agency in West Africa have not updated
their training on current good manufacturing practice
(cGMP) inspection in at least eight years except the
last two years (2017 & 2018) but have relied on
learning-on-the job skills by themselves without
proper mentorship for the same said period. The
agency is a statutory organ of the Federal government
established by an Act and charged with the
responsibility for regulation of Pharmacy practice in all
aspects and ramifications(Usar et al., n.d.). This
includes regulating and controlling pharmacy
education, practice and training. The duties of the
agency include but are not limited to
•
•

•

registration and licensure of all pharmacists;
registration and licensure of pharmaceutical
premises
(manufacturing,
importation,
distribution, wholesale, retail and hospital
pharmacies);
registration of pharmacy technicians and
issuance of permit to the registered pharmacy
technicians and finally, registration and licensure
of patent and proprietary medicine vendors.

This means that anybody who wants to register or
own a pharmaceutical premises/business of any kind,
including Patent and Proprietary Medicine Vendor
shop or is seeking to be registered as a pharmacist or
pharmacy technician in the country must be

registered
and
certified
by
the
agency.
(www.pharmapproach.com, www.pcn.gov.ng). It also
means that the agency inspects all the
pharmaceutical facilities including manufacturing
industries, for the purpose of licensure. The agency
has several departments including inspection and
monitoring (I&M) department. The I&M department is
in charge of inspections. For inspections of new
manufacturing facilities and multinationals, the lead
inspector is always the Head of Department of the
I&M. For subsequent routine inspections and others,
it becomes the responsibility of the state officers (staff
of the agency in charge of that state) where the
facilities are domiciled, coordinated by the zonal
officers. These State Officers handle other regulatory
activities of the agency in their respective states in
addition to the GMP inspections. There are different
categories of practice of pharmacy and these include;
retail,
wholesale/distribution,
importation
and
manufacturing. Except for manufacturing, the process
of registration for pharmacies is the same. The first
thing the applicant completes is application for a
location inspection. Location inspection and
subsequent approval is a prerequisite to a preapproval or facility inspection. The second step, if the
location is given approval is for the applicant to apply
for a pre-approval inspection/ registration. After the
pre-approval inspection, any compliance directive
issued must be fully attended to by the applicant and
the corrective measures put in place before approval
is given. Nonetheless in some states, after the
location is approved, the applicant may be told to
submit an application letter for pre-approval/facility
inspection. When this happens and the facility is
approved, the applicant often is tempted to continue
with business as usual, without recourse to proper
registration. In this case, the premises/company can
be regarded as an illegal premise because due
process was not followed before commencing
business. In some states, applicants are told to apply
for
both
location
and
facility
inspection
simultaneously, in which case the inspector attempts
inspecting the location and the facility at the same
time, again without recourse to the fact that the
location inspection and subsequent approval is a
prerequisite to the facility inspection.
Aim of the study
This research was aimed at a retrospective study of
the GMP inspection report of a Regulatory Agency in
West Africa that regulates the pharmacy practice, to
ascertain conformances with the GMP inspection
format which determines the proficiency of the
inspectors and the system. This was done through
gap analysis of the inspection report within a given
period of time.
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Objectives
•
•
•
•
•

To identify gaps in inspector training that
should be addressed to improve quality and
insure uniformity of inspection activities
Identify if gaps are attributable to the system
or individual inspectors
To compare the WHO GMP checklist with that
of the Agency with the intention of reviewing
the latter
To evaluate the report writing skills and
competency of the inspectors
To determine the effect of inspector GMP
training and make appropriate training
recommendations.

Research questions
•

•

What implication,
if
any did
non
conformances and non-uniformity in GMP
inspection activities have on the regulatory
system?
What implication if any, did the contents of the
GMP report have on the regulatory function of
the agency and the industry or the regulated?

2. METHODS
Inspection reports from States are kept in the head
office and are physically filed, state by State. State
offices also keep records of the reports they sent to
the head office.
Sampling took place in two phases;
Files from the six geopolitical zones domiciled at the
head office of the agency were evaluated. In one of
the zones there was no manufacturing industry at the
time of this study. Even in those geopolitical zones
that have manufacturing industries, some States do
not have manufacturing industries. Sampling was
randomly done (the first report then after every five
report the sixth was considered). For every file that
was sampled, it was sampled exhaustively. For the
first phase, a total of 35 reports from the six
geopolitical zones were studied as follows;
For South-South zone, two reports were considered
each for Edo and Rivers states. For South - East
zone, the state that have manufacturing industries
were; Enugu, Anambra and Imo states. Three reports
were sampled from Enugu state and four each from
Anambra and Imo states respectively. In the northwest zone, five reports were sampled from Kano state
and one from Kaduna state. North Central zone has
only one state, Kwara where four inspection reports
were sampled. In the south-west, four and six
inspection reports were sampled from Ogun and

Lagos states respectively.
North East had no
pharmaceutical manufacturing industry at the time of
this research. The report studied covered a period of
2013 to 2019.
For the second phase, four soft copies of inspection
reports report were requested from officers of the
agency manning the states (state officers). For those
that forwarded the four reports, two reports were
randomly selected. For those that sent one or two, all
were considered making a total of 15 reports as
shown below:
South-West;- Ogun State two reports, Lagos State
two reports;
South-East; two reports each for Anambra and Imo
states;
South-South: one report each for Edo and Rivers
States;
North-Central: one inspection report each for Niger
and Kwara States.
North-West: Kano State two inspection report;
North-East: has no manufacturing industry.
This phase looked at the proficiency of the inspection
activities and the inspectors themselves. The
indicators or components of the inspection checklist
were considered and awarded one mark each. In
assessing the report, an indicator that was attended
to appropriately had a full mark and that which was
not fully attended to was awarded 0.5. Indicators are
items on the inspection checklist. Fully attending to
an indicator meant everything that an item is required
to project during inspection may have been captured
in the report of an inspection without ambiguity
(www.who.int). All indicators and sub indicators were
assigned a mark of 1 each. For example, if the sub
indicators were 8, the number of sub indicators
attended to will be divided by the total number of sub
indicators under that major indicator or GMP
component as shown here 8/8 = 1. The percentage
per report was obtained.
3. RESULTS

AND DISCUSSION

Phase 1
The components of the GMP checklist of the agency
and the indicators under those components were
reviewed as per the proficiency of the activities of the
inspectors as it affects the quality of the inspection
report. Observations made on all of the sub indicators
under the major indicators/components (general
information, factory layout, organizational chart,
building and premises, packaging materials, good
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practice in production, equipment, quality control,
sanitation and hygiene, safety measures and
distribution) were considered during the gap analysis

Figure 1 shows the major indicators (GMP
components) and the total number of sub-indicators
under them, with building and premises having the
largest number of sub indicators under it. The
reviewed agency's checklist in relation with the World
Health Organization (WHO) checklist indicated that
there is a need to rearrange the sub-indicators and
place some under their appropriate GMP
components8 . For example, health requirements for
personnel was placed under “organization and
personnel” instead of GMP component “personal
hygiene” (www.mcrhrdi.gov.in)

Figure 1. Number of indicators under components
against the major GMP components
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Figure 2. A histogram showing a plot of percentage of non-conformance against indicators under general
information component of the GMP inspection format indicators
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Under general information (Fig 2), it was observed
that 34.29% of the report did not address the
licensure status of the superintendent or supervising
pharmacists
and
the
pharmacist
director
respectively.

31.43% of the accessed and assessed reports did
not address the issue of the licensure of the
company. 28.57% ignored batch size. This shows
that attention was not given to the full indicators by
other inspection reports.

a;,

0.0

cc
_,_.,

=
a;,

~

II

48.57

48.57

II

28.47

I

I

5.71

Cl

20

OJ

c::

Cl

8.57

Cl

34.29

28.57

-=
-=

28.57

§

Cl

34.29

OJ

cc

40

=

37.14

42.86

57.14

Figure 3. A histogram showing a plot of percentage of non-conformance against indicators under factory layout
component of the GMP inspection format indicator.

I

I

a;,

a...

Under the factory layout component, (Figure 3)
28.47% of the reports ignored the B-lactam
sensitivity test for staff which was a critical area that
could affect the product and the patients. Also
37.14% under this component ignored the drainage
system which is also critical and may result in a
source of contamination. The design of a
manufacturing plant should be done in such a way to
prevent contamination or unsanitary condition.
57.14% of the total report assessed did not make
more observations in addition to the guide captured
by the check list. This indicated the level of
competency and proficiency of the inspectors in
inspection activities
In region of West Africa where this study was done,
it was observed that the major source of water for

pharmaceutical factories was boreholes. It is
pertinent to note that the Medicine Regulatory
Agency (MRA) in the country pegs the depth of
boreholes at not less than 150ft and 50m from a
cesspool (www.nafdac.gov.ng), probably because
the depth of a borehole and its proximity to a septic
tank may affect the product(Chove et al., 2017). This
showed that the source of water and its treatment
was a critical point in production of pharmaceuticals
and must be closely monitored during inspection to
make sure that specifications are strictly adhered to.
Any borehole short of the above standards cannot be
recommended for use in the production of
pharmaceutical products.
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Figure 4. A histogram showing a plot of percentage of non-conformance against indicators under building and
premises component of the GMP inspection format.
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Unfortunately, Fig 4 indicates that 34.29% of the total
reports assessed did not say anything about the
depth of boreholes, 40% of the report did not indicate
whether the water was given primary or secondary
treatment. 37.14% provided no information about the
availability of trained personnel for water treatment.
This is an indication that the companies may not be
guided appropriately at the end of such inspection
activities. Again, the majority of the reports assessed

were for routine inspections that supposedly covered
the whole factory. Figure 4 also showed a trending
line which indicated that non conformances were
increasing steadily with time.
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Figure 5. A histogram showing a plot of percentage of non-conformance against indicators under packaging
material/good practice in production component of the GMP inspection format
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Figure 5 above indicates that 34.29% did not report
on vendor supplier audit and line clearance
respectively. In the current GMP regulation, the
pharmaceutical manufacturer is expected to take
responsibility for the entire manufacturing process
including quality of components like APIs, excipients
and packaging materials (Patel & Chotai, 2010).This
implies that the manufacturer of the finished product
must be sure of the source of materials and this calls
for vendor audit and qualification. 20% of the reports
did not report on the qualification and calibration of
equipment which is also very critical and may be a
source of error (Losada-Urzáiz et al., 2015). One of
the essences of Quality Assurance (QA) is to ensure
that adequate controls for all materials including
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I

20
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packaging materials and processes are put in
place(Chaudhari et al., 2014). Unfortunately, 42.86%
of the inspectors or reports ignored records of
packaging materials and did not give any report on
the indicator as indicated in Figure 5.
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Figure 6. A histogram showing a plot of percentage of non-conformance against indicators under equipments,
quality and control and sanitation and hygiene component of the GMP inspection format.

a..

Figure 6 covers indicators under three major
indicators or components of the GMP check list.
These include equipment, quality control and
sanitation/hygiene; 37.14% of the reports did not give
any report on validations and standard operating
procedures respectively.
Validation is a key
parameter of the GMP (Kumar & Bharat, 2013).
Standard Operating Procedures (SOP) are a
regulatory requirement in the pharmaceutical
industries. One of their aims is to ensure that
consistent quality control of processes and products
are maintained through the operations performed.
(Bhattacharya & Phill, 2015). Thus validation and
SOPs are vital components of GMP and should not
be ignored during inspections. Under these same
GMP components, 31.45% of the reports ignored the
preventive maintenance records and Batch
Manufacturing Records. Preventive maintenance is
defined as an activity of maintenance that focuses on
retaining the workability of a part of a technical
system while corrective maintenance rather focuses
on restoring the part of a system to its workable state
(Percy et al., 1997). Preventive maintenance
improves the reliability of the manufacturing system
and lowers cost (Meller & Kim, 1996) and this is
achieved because preventive maintenance greatly

reduces the down time. Batch manufacturing records
are also critical parameters never to be ignored
during routine inspections. A batch is a specific
quantity of a drug or other materials that is intended
to have uniform character and quality within specified
limits and is produced according to a single
manufacturing order during the cycle of
manufacture(Chatterjee,
2012).
Also,
in
manufacturing, batch processing is the processing of
raw materials with the end points determined in
advance. So fraud, as regards to the quality of the
process and subsequently the end product can be
detected through a well-developed process control
technique for batches (Tsung et al., 2007).
Inspection reports depicts what happened during
inspection activities. The above results show
discretional inspection activities by inspectors in
different or same zones. There were no reasons
provided in the report in those circumstances where
indicators/sub indicators were not attended to during
the
inspections.
This
depicted
subjective
interpretation rather than being objective. The
manufacturers will be confused, especially in a
situation where different inspectors had different
approaches to inspection activities and ignored other
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GMP indicators and vice versa without reasons. The
concern here was whether non-conformity can be
addressed in companies when inspectors
themselves do not conform to the GMP inspection
format or check list.

87.51

83.6 35.64 89.4

83.13

88.31

Phase 2

74.84
82.11 80.44

84.82

In the second phase, a scoring format was
developed.
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• R1 • R2

Figure 7. Scores (%) from the different inspection
report assessed in the second phase samples.
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Figure 7 represents the scores of the inspection
reports. Different inspection reports had different
scores ranging from 35.64 to 89.40. The wide
discrepancies in the inspection reports, was a
confirmation that the inspectors are not on the same
page.
Figure 8. Scores and year inspections were done
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It was significant the reports that scored 80% and
above were inspection reports that were done in
2018 and 2019 (Figure 8). It was noteworthy that in
year 2017, 2018 and 2019, about 17 % of the
inspectors were trained. Coincidently a majority of
those reports for the second phase came from those
regions where inspectors were recently trained. 4%
out of the 17% trained inspectors produced the
reports that scored 80% and above. However,
behavioral changes following trainings may be short
lived without activities to support transfer (Martin,
2010). In view of this and in order to make the training
effective and impactful on the organization there was
the need to promote transfer of skills and knowledge
from trainings to the work place. To make training
impactful, there are variables that must be taken into
consideration as follows; program design, trainee
characteristics, work place environment and followup activities. In designing the training program, the
trainees may have to be carried along by assuring
them that they will practice the acquired skills or
apply the knowledge gained during the training. The
self-efficacy and motivation (characteristics) of the
staff involved in training also played a role.
Additionally, work place environment like the
employee supervisor attitude, technical support and
consequences of using training on the job affected
training transfer. It had been observed that an
unfavorable or unfriendly post training environment
can jeopardize the transfer of training(Tannenbaum
& Yukl, 1992). Follow-up activities are the most
important in transferring training to the workplace.
Example of follow-up activities includes action plan,
performance assessment, supervisory consultations
and technical support from the supervisors and/or
the management.

4. CONCLUSION
The results of the study showed non-conformances
across
35
inspection
reports
reviewed
retrospectively which inferred non-conformances in
inspection activities across the country as shown in
Figures 1 – 6 as per percentage non-conformances
of varying degrees in the indicators under various
components of the GMP inspection report format. In
Figure 4, the straight line cutting across the
histograms was called the trending line. The trend
line showed increasing non conformances with time.
This trend is expected to continue if no action is
taken. Also, there was a slight deviation in placing
sub indicators under their GMP components in the
Agency’s GMP inspection report format as compared

to the WHO GMP check list and the GMP practices
observed at a manufacturing company in East Africa,
during my internship, with the existing checklist of
the Agency.
In order to eliminate the non-conformances, there is
a need to regularly and consistently train inspectors
in regards to inspection activities and inspection
report writing to make sure they are on the same
page. The work reported here demonstrates that,
training will be an effective solution to reduce nonconformances. The goal was to reduce or eliminate
non conformances in inspection activities as it
reflected in the inspection reports. Effective training
lead(s) to an enthusiastic, more satisfied and
engaged workforce which finally translates to the
efficiency of the system (Training, 2019). In order to
produce quality-assured medicines in Africa,
capabilities must be built both for Regulators and
pharmaceutical industries (Fortunak et al., 2010).
The guidelines on training and qualification of GMP
inspectors provided that, inspectors should be well
trained in all the relevant areas and
be
knowledgeable in topics of manufacturing processes,
control and distribution of medicinal products, quality
assurance management, investigational inspection
and inspection methodology (www.ec.europa.eu).
Again, the Pharmaceutical Inspection Convention
(PIC) or Pharmaceutical Inspection Cooperative
Scheme (PIC/S) in one of their annual report stated
that in order to achieve uniform interpretation and
application of GMP, training of GMP inspectors
remains an essential tool. The report stressed that
only harmonization of GMP requirement through
PIC/S GMP guide was not sufficient to achieve that
(www.picsheme.org). The populations of every
country on the globe have right to access of safe,
efficacious, good quality and affordable medicines,
which can only be ensured through competent and
effective regulations by the National Medicines
Regulatory
Agencies
(NMRAs)
of
those
countries(Ndomondo-Sigonda et al., 2017). This
indicated that the importance of training cannot be
overemphasized. Figure 8 demonstrated the benefit
of training as most of the reports that scored high
marks in the second phase of the study were from
the regions where inspectors were recently trained,
indicating the importance and benefits of training.
However, there was a Lack of objective
interpretations in reporting which was an indication of
lack of proficiency and or competence in inspection
activities, reporting skills and the ability to interpret
findings. Inspections are tools for assessment put in
place by Regulatory Authorities and other standard

14
bodies to monitor external organization e.g.
pharmaceutical premises, under their jurisdiction
(Vaishnavi K., 2011). The primary goal for any
pharmaceutical inspector is to achieve GMP
compliance as regards market authorization
(Vaishnavi K., 2011). An inspection should be
corrective, motivational and educational to the
regulated. Inspection activities should be beyond
disclosure of faults, deficiencies and discrepancies.
To achieve the goal of inspections, that are,
corrective, motivational and educational, there is an
absolute need for trainings and retraining not only in
the inspection activities but in inspection-report
writing and interpretation of observations because of
the evolving nature of the GMP.
Furthermore, there is need to review the Agency’s
GMP checklist and make it more robust in line with
best global practices in GMP.

RECOMMENDATIONS
STEPS

5.

In order to minimize and or
conformances,
the
following
recommended:

FOR

NEXT

eliminate non
actions
are

1. Train and re-train inspectors in inspection
activities because of the evolving nature of
GMP;
2. Train inspectors on interpretation of
observations or findings and GMP inspection
report writing;
3. Review the GMP inspection format in line
with the WHO GMP inspection check list to
make it more robust and uniform;
4. Number the pages of the reviewed GMP
inspection format to prevent tampering in
terms of removal or addition of information
except by authorized committee;
5. Provide periodic training for key industrial
personnel to keep them abreast of evolving
GMP issues. This will contribute to more
friendly and interactive inspections;
6. Require all submitted report must to be
signed by the inspectors that participated in
the inspection;
7. Develop rubrics for rating GMP inspectors.
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